PEXIVAS challenges current ANCA-associated vasculitis therapy

Nature Reviews Nephrology, Published online: 13 March 2020; doi:10.1038/s41581-020-0269-6The PEXIVAS clinical trial demonstrated that, in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV), adjuvant plasma exchange did not reduce the risk of all-cause mortality or end-stage kidney disease and a reduced dose of glucocorticoids was not inferior to standard dosing. These findings might warrant a change in standard AAV therapy.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research